Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 708

1.

APOE genotype regulates pathology and disease progression in synucleinopathy.

Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, Haines JN, Dhavale DD, Miller R, Choudhury FA, Sullivan PM, Cruchaga C, Perlmutter JS, Ulrich JD, Benitez BA, Kotzbauer PT, Holtzman DM.

Sci Transl Med. 2020 Feb 5;12(529). pii: eaay3069. doi: 10.1126/scitranslmed.aay3069.

PMID:
32024799
2.

Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.

Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, Cella M, Ulland TK, Zaitsev K, Miyashita A, Ikeuchi T, Sainouchi M, Kakita A, Bennett DA, Schneider JA, Nichols MR, Beausoleil SA, Ulrich JD, Holtzman DM, Artyomov MN, Colonna M.

Nat Med. 2020 Jan;26(1):131-142. doi: 10.1038/s41591-019-0695-9. Epub 2020 Jan 13.

PMID:
31932797
3.

Publisher Correction: Dietary salt promotes cognitive impairment through tau phosphorylation.

Faraco G, Hochrainer K, Segarra SG, Schaeffer S, Santisteban MM, Menon A, Jiang H, Holtzman DM, Anrather J, Iadecola C.

Nature. 2020 Feb;578(7793):E9. doi: 10.1038/s41586-019-1925-5.

PMID:
31932732
4.

Dementia is not synonymous with Alzheimer's disease.

Jack CR Jr, Holtzman DM, Sperling R.

Sci Transl Med. 2019 Dec 11;11(522). pii: eaav0511. doi: 10.1126/scitranslmed.aav0511. No abstract available.

PMID:
31826979
5.

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease.

Llibre-Guerra JJ, Li Y, Schindler SE, Gordon BA, Fagan AM, Morris JC, Benzinger TLS, Hassenstab J, Wang G, Allegri R, Berman SB, Chhatwal J, Farlow MR, Holtzman DM, Jucker M, Levin J, Noble JM, Salloway S, Schofield P, Karch C, Fox NC, Xiong C, Bateman RJ, McDade E.

JAMA Netw Open. 2019 Dec 2;2(12):e1917126. doi: 10.1001/jamanetworkopen.2019.17126.

6.

Gut microbiota: from the forgotten organ to a potential key player in the pathology of Alzheimer disease.

Seo DO, Holtzman DM.

J Gerontol A Biol Sci Med Sci. 2019 Nov 18. pii: glz262. doi: 10.1093/gerona/glz262. [Epub ahead of print]

PMID:
31738402
7.

Dietary salt promotes cognitive impairment through tau phosphorylation.

Faraco G, Hochrainer K, Segarra SG, Schaeffer S, Santisteban MM, Menon A, Jiang H, Holtzman DM, Anrather J, Iadecola C.

Nature. 2019 Oct;574(7780):686-690. doi: 10.1038/s41586-019-1688-z. Epub 2019 Oct 23. Erratum in: Nature. 2020 Feb;578(7793):E9.

PMID:
31645758
8.

Targeting tauopathy with engineered tau-degrading intrabodies.

Gallardo G, Wong CH, Ricardez SM, Mann CN, Lin KH, Leyns CEG, Jiang H, Holtzman DM.

Mol Neurodegener. 2019 Oct 22;14(1):38. doi: 10.1186/s13024-019-0340-6.

9.

Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model.

Huynh TV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM, Finn MB, Spellman R, Manis M, Tanzi RE, Ulrich JD, Holtzman DM.

Mol Neurodegener. 2019 Oct 17;14(1):37. doi: 10.1186/s13024-019-0337-1.

10.

Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model.

Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, Holtzman DM.

J Exp Med. 2019 Nov 4;216(11):2546-2561. doi: 10.1084/jem.20190980. Epub 2019 Oct 10.

PMID:
31601677
11.

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Long JM, Holtzman DM.

Cell. 2019 Oct 3;179(2):312-339. doi: 10.1016/j.cell.2019.09.001. Epub 2019 Sep 26. Review.

PMID:
31564456
12.

The microbiome: A target for Alzheimer disease?

Seo DO, Boros BD, Holtzman DM.

Cell Res. 2019 Oct;29(10):779-780. doi: 10.1038/s41422-019-0227-7. No abstract available.

PMID:
31488883
13.

Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors.

Wang C, Holtzman DM.

Neuropsychopharmacology. 2020 Jan;45(1):104-120. doi: 10.1038/s41386-019-0478-5. Epub 2019 Aug 13. Review.

PMID:
31408876
14.

Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains.

Xu J, Sun J, Perrin RJ, Mach RH, Bales KR, Morris JC, Benzinger TLS, Holtzman DM.

Ann Clin Transl Neurol. 2019 Aug;6(8):1423-1434. doi: 10.1002/acn3.50837. Epub 2019 Jul 9.

15.

A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain.

Del-Aguila JL, Li Z, Dube U, Mihindukulasuriya KA, Budde JP, Fernandez MV, Ibanez L, Bradley J, Wang F, Bergmann K, Davenport R, Morris JC, Holtzman DM, Perrin RJ, Benitez BA, Dougherty J, Cruchaga C, Harari O.

Alzheimers Res Ther. 2019 Aug 9;11(1):71. doi: 10.1186/s13195-019-0524-x.

16.

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.

Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ.

Neurology. 2019 Oct 22;93(17):e1647-e1659. doi: 10.1212/WNL.0000000000008081. Epub 2019 Aug 1.

PMID:
31371569
17.

TREM2 function impedes tau seeding in neuritic plaques.

Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, Manis M, Colonna M, Lee VMY, Ulrich JD, Holtzman DM.

Nat Neurosci. 2019 Aug;22(8):1217-1222. doi: 10.1038/s41593-019-0433-0. Epub 2019 Jun 24.

18.

Trends in prevalence of protective levels of hepatitis B surface antibody among adults aged 18-49 years with risk factors for hepatitis B virus infection-United States, 2003-2014.

King H, Xing J, Dean HD, Holtzman D.

Clin Infect Dis. 2019 Jun 20. pii: ciz537. doi: 10.1093/cid/ciz537. [Epub ahead of print]

PMID:
31228240
19.

Senescent glia spell trouble in Alzheimer's disease.

Holtzman D, Ulrich J.

Nat Neurosci. 2019 May;22(5):683-684. doi: 10.1038/s41593-019-0395-2. No abstract available.

PMID:
31024116
20.

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease.

Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, Chhatwal JP, Noble JM, Ringman JM, Graff-Radford NR, Holtzman DM, Ladenson JH, Morris JC, Bateman RJ, Xiong C, Fagan AM; Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2019 May;15(5):655-665. doi: 10.1016/j.jalz.2018.12.019. Epub 2019 Mar 4.

PMID:
30846386
21.

Dural lymphatics regulate clearance of extracellular tau from the CNS.

Patel TK, Habimana-Griffin L, Gao X, Xu B, Achilefu S, Alitalo K, McKee CA, Sheehan PW, Musiek ES, Xiong C, Coble D, Holtzman DM.

Mol Neurodegener. 2019 Feb 27;14(1):11. doi: 10.1186/s13024-019-0312-x.

22.

Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.

Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR, Ances BM, Berman SB, Brosch JR, Galasko D, Gauthier S, Lah JJ, Masellis M, van Dyck CH, Mintun MA, Klein G, Ristic S, Cairns NJ, Marcus DS, Xiong C, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Brain. 2019 Apr 1;142(4):1063-1076. doi: 10.1093/brain/awz019.

PMID:
30753379
23.

Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1.

Strickland MR, Holtzman DM.

J Clin Invest. 2019 Mar 1;129(3):969-971. doi: 10.1172/JCI127578. Epub 2019 Feb 11.

24.

Multi-Modal Home Sleep Monitoring in Older Adults.

Toedebusch CD, McLeland JS, Schaibley CM, Banks IR, Boyd J, Morris JC, Holtzman DM, Lucey BP.

J Vis Exp. 2019 Jan 26;(143). doi: 10.3791/58823.

25.

Reply to "obstructive sleep apnea treatment and amyloid-β in cerebrospinal fluid".

Ju YS, Holtzman DM.

Ann Neurol. 2019 Mar;85(3):460-461. doi: 10.1002/ana.25424. Epub 2019 Feb 19. No abstract available.

PMID:
30706528
26.

The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans.

Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller PM, Lucey BP, Holtzman DM.

Science. 2019 Feb 22;363(6429):880-884. doi: 10.1126/science.aav2546. Epub 2019 Jan 24.

PMID:
30679382
27.

"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia".

Jagust W, Jack CR Jr, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Sperling R.

Alzheimers Dement. 2019 Jan;15(1):153-157. doi: 10.1016/j.jalz.2018.11.002. No abstract available.

PMID:
30642435
28.

The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA.

Coyle C, Moorman AC, Bartholomew T, Klein G, Kwakwa H, Mehta SH, Holtzman D.

Hepatology. 2019 Aug;70(2):476-486. doi: 10.1002/hep.30501. Epub 2019 Mar 26.

PMID:
30633811
29.

Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease.

Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TLS, Holtzman DM.

Sci Transl Med. 2019 Jan 9;11(474). pii: eaau6550. doi: 10.1126/scitranslmed.aau6550. Erratum in: Sci Transl Med. 2020 Jan 8;12(525):.

30.

Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE.

Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Müller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, Ertürk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M, Haass C.

Nat Neurosci. 2019 Feb;22(2):191-204. doi: 10.1038/s41593-018-0296-9. Epub 2019 Jan 7.

31.

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.

Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C.

JAMA Neurol. 2019 Mar 1;76(3):264-273. doi: 10.1001/jamaneurol.2018.4249.

32.

Obstructive sleep apnea treatment, slow wave activity, and amyloid-β.

Ju YS, Zangrilli MA, Finn MB, Fagan AM, Holtzman DM.

Ann Neurol. 2019 Feb;85(2):291-295. doi: 10.1002/ana.25408. Epub 2019 Jan 17.

33.

New insights into the role of TREM2 in Alzheimer's disease.

Gratuze M, Leyns CEG, Holtzman DM.

Mol Neurodegener. 2018 Dec 20;13(1):66. doi: 10.1186/s13024-018-0298-9. Review.

34.

Amyloid-β 'seeds' in old vials of growth hormone.

Huynh TV, Holtzman DM.

Nature. 2018 Dec;564(7736):354-355. doi: 10.1038/d41586-018-07604-6. No abstract available.

PMID:
30546137
35.

Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.

Babulal GM, Chen S, Williams MM, Trani JF, Bakhshi P, Chao GL, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Morris JC, Roe CM.

J Alzheimers Dis. 2018;66(3):1213-1221. doi: 10.3233/JAD-180564.

36.

High-affinity interactions and signal transduction between Aβ oligomers and TREM2.

Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD, Colonna M, Golde TE.

EMBO Mol Med. 2018 Nov;10(11). pii: e9027. doi: 10.15252/emmm.201809027.

37.

Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.

Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV.

Mol Neurodegener. 2018 Oct 19;13(1):57. doi: 10.1186/s13024-018-0286-0.

38.

Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.

Roe CM, Ances BM, Head D, Babulal GM, Stout SH, Grant EA, Hassenstab J, Xiong C, Holtzman DM, Benzinger TLS, Schindler SE, Fagan AM, Morris JC.

Brain. 2018 Nov 1;141(11):3233-3248. doi: 10.1093/brain/awy244.

39.

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.

McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network.

Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.

40.

Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Shi Y, Holtzman DM.

Nat Rev Immunol. 2018 Dec;18(12):759-772. doi: 10.1038/s41577-018-0051-1. Review.

41.

In Search of an Identity for Amyloid Plaques.

Huynh TV, Holtzman DM.

Trends Neurosci. 2018 Aug;41(8):483-486. doi: 10.1016/j.tins.2018.06.002.

PMID:
30053949
42.

Intercellular Spread of Protein Aggregates in Neurodegenerative Disease.

Davis AA, Leyns CEG, Holtzman DM.

Annu Rev Cell Dev Biol. 2018 Oct 6;34:545-568. doi: 10.1146/annurev-cellbio-100617-062636. Epub 2018 Jul 25. Review.

43.

Twos and Threes: Musical Chairs in Female Psychic and Social Life.

Kulish N, Holtzman D.

J Am Psychoanal Assoc. 2018 Jun;66(3):443-472. doi: 10.1177/0003065118777245.

PMID:
29975143
44.

Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP.

Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, Chávez-Gutiérrez L, Cleverley K, Noy S, Sheppard O, Collins T, Powell C, Sarell CJ, Rickman M, Choong X, Tosh JL, Siganporia C, Whittaker HT, Stewart F, Szaruga M; London Down syndrome consortium, Murphy MP, Blennow K, de Strooper B, Zetterberg H, Bannerman D, Holtzman DM, Tybulewicz VLJ, Fisher EMC; LonDownS Consortium.

Brain. 2018 Aug 1;141(8):2457-2474. doi: 10.1093/brain/awy159. Erratum in: Brain. 2019 Jun 1;142(6):e25.

45.

Using the A/T/N Framework to Examine Driving in Preclinical AD.

Roe CM, Babulal GM, Stout SH, Ott BR, Carr DB, Williams MM, Benzinger TLS, Fagan AM, Holtzman DM, Ances BM, Morris JC.

Geriatrics (Basel). 2018 Jun;3(2). pii: 23. doi: 10.3390/geriatrics3020023. Epub 2018 May 2. No abstract available.

46.

AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.

Hettinger JC, Lee H, Bu G, Holtzman DM, Cirrito JR.

Mol Neurodegener. 2018 May 15;13(1):22. doi: 10.1186/s13024-018-0256-6.

47.

White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease.

Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Fӧrster S, Schofield PR, Sperling RA, Johnson KA, Chhatwal JP, Salloway S, Correia S, Jack CR Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM; Dominantly Inherited Alzheimer Network.

PLoS One. 2018 May 9;13(5):e0195838. doi: 10.1371/journal.pone.0195838. eCollection 2018.

48.

Dual therapy for Aβ amyloidosis in AD: A successful one-two combo.

Patel TK, Holtzman DM.

J Exp Med. 2018 May 7;215(5):1267-1268. doi: 10.1084/jem.20180494. Epub 2018 Apr 23.

49.

Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype.

Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC, Benzinger TLS, Gordon BA.

Brain. 2018 Jun 1;141(6):1828-1839. doi: 10.1093/brain/awy103.

50.

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors.

Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.

Supplemental Content

Loading ...
Support Center